Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand.
Studies involving modifications to the P3 position of previously described HIV-protease inhibitors containing beta-hydroxyether and thioether dipeptide isostere replacements led to the discovery of pseudopeptides 8o and 8p with improved antiviral activities.
Patel
N M
NM
Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Bennett
F
F
Girijavallabhan
V M
VM
Dasmahapatra
B
B
Butkiewicz
N
N
Hart
A
A
D004151:Dipeptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004987:Ethers; D006678:HIV / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008968:Molecular Conformation; D015394:Molecular Structure; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D004151:Dipeptides; D004987:Ethers; D017320:HIV Protease Inhibitors